Fabrication and Characterisation of gemcitabine hydrochloride loaded magnetically responsive mesoporous silica nanocomposites as smart hybrid theranostic platform for treatment of pancreatic cancer
Source abstract
Abstract
The research aims at the fabrication and characterisation of magnetically responsive mesoporous silica nanocomposites (MSNs), which can play therapeutic and diagnostic (theranostic) roles simultaneously. The ultimate goal was to create a smart hybrid stimuli-responsive nano cargo that can be used for diagnostic purposes and the therapeutic action of which can be controlled. Magnetic nanoparticles were synthesised by the green synthesis, and mesoporous silica nanoparticles were obtained using the sol–gel method. The nanoparticles were further functionalised using (3-aminopropyltriethoxysilane). Physicochemical characterisation of the drug-loaded MSNs was performed using sophisticated analytical techniques such as infrared spectroscopy, particle size analysis, transmission electron microscopy, drug uptake studies, fluorescence microscopy and BET analysis. The particle size of SBA-15 was found to be 98 nm. The surface area of SBA-15 was 459.79 m2/gm. The drug-loaded SBA-15 showed a 49.3% drug release within 10 h in phosphate buffer of pH 7.4.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Graphene and Nanomaterials Applications · Dendrimers and Hyperbranched Polymers
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Pharmaceutics, Sanjivani College of Pharmaceutical Education and Research, Pune University, Kopargaon, India
Department of Pharmacology, Sanjivani College of Pharmaceutical Education and Research, Pune University, Kopargaon, India
Department of Pharmaceutics, MAAERS, Maharashtra Institute of Pharmacy, Kothrud, India
Funding
Department of Science and Technology, Ministry of Science and Technology
References (20)
Show source-provided references
1. Hasan S. · Res J Recent Sci · 2005 · 4 · 9
2. 10.4103/2230-973X.16084410.4103/2230-973X.160844 ↗
3. 10.1016/S0168-3659(00)00339-410.1016/S0168-3659(00)00339-4 ↗
4. 10.1038/4221810.1038/42218 ↗
5. 10.1126/science.284.5417.114310.1126/science.284.5417.1143 ↗
6. 10.1038/nrd163210.1038/nrd1632 ↗
7. 10.1016/j.progpolymsci.2003.12.00210.1016/j.progpolymsci.2003.12.002 ↗
8. 10.1038/nbt117110.1038/nbt1171 ↗
9. Lee CC · Eur J Pharm Biopharm · 50 · 27
10. 10.1002/adma.20050161210.1002/adma.200501612 ↗
11. 10.1021/ja028650l10.1021/ja028650l ↗
12. 10.1002/smll.20090178910.1002/smll.200901789 ↗
13. 10.1080/10667857.2018.151278210.1080/10667857.2018.1512782 ↗
14. Panage S · Pharm Lett · 2014 · 6 · 159
15. 10.2147/OTT.S11381510.2147/OTT.S113815 ↗
16. 10.1088/1361-6528/aa66b010.1088/1361-6528/aa66b0 ↗
17. 10.1039/C4TB00919C10.1039/C4TB00919C ↗
18. Chin SF · J Mater Environ Sci · 2011 · 2 · 299
19. Pandey R · Res J Pharm Biol Chem Sci · 2013 · 4 · 145
20. 10.1080/10667857.2018.153818610.1080/10667857.2018.1538186 ↗